Stock market correction sends biopharma back to the start of 2021
Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.
Precision’s itinerant Car-T cells go on another journey
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
Merck’s Covid-19 push narrows further
Merck & Co gives up on MK-7110, and on molnupiravir in hospitalised patients.
Medtech
A new market beckons for Alzheimer’s blood tests
If drugs acting on amyloid and tau can defy the sector’s history of failure, the testing landscape will change dramatically.
Company Events
Macrogenics takes another shot at a novel immune checkpoint
Having failed with orlotamab, and with enoblituzumab’s potential narrowing, Macrogenics generates interest around MGC018.
Vertex’s second try at a rare lung disorder
A small molecule for alpha-1 antitrypsin deficiency faces a key clinical test, and its chances of success aren’t good.
Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
Interviews
C4X shows being early to the party can bring success
Very early stage deals could be the way for C4X to avoid the funding desert that has scuppered so many other UK biotechs.
Prilenia hopes to buck the Huntington’s trend
Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.
